- CytoMed Therapeutics Limited announced on **October 2, 2025**, the **publication of collaborative research** with The University of Texas, MD Anderson Cancer Center, demonstrating the potential of the Company’s **Allogeneic γδ T Cells (CTM-GDT) to treat Acute Myeloid Leukemia (AML)**.  **[1873093_0001493152-25-016599_form6-k.htm:0]** **[1873093_0001493152-25-016599_ex99-1.htm:0]** 
- The study, titled "_Donor-Derived Vγ9Vδ2 T Cells for Acute Myeloid Leukemia: A Promising 'off-the-shelf' Immunotherapy Approach_", provides the **rationale for further clinical study** of allogeneic donor-derived γδ T cells in treating AML and other cancers.  **[1873093_0001493152-25-016599_ex99-1.htm:0]** 
- CytoMed plans to **advance this γδ T cell-based product into clinical trials** in Southeast Asia, following its leading product, CAR-γδ T cells (CTM-N2D), which is currently undergoing a Phase 1 clinical trial in Singapore.  **[1873093_0001493152-25-016599_ex99-1.htm:0]**

CytoMed Therapeutics Announces Publication of Collaborative Research on AML Treatment

- For the six months ended June 30, 2025, CytoMed Therapeutics Ltd reported a **net loss of S$2,245,828 (U.S.$1,765,727)**, significantly higher than S$1,088,543 in the prior year period, while generating its first revenue of **S$155,887 (U.S.$122,562)** mainly from private blood banking services.  **[1873093_0001493152-25-016169_ex99-1.htm:1]** **[1873093_0001493152-25-016169_ex99-2.htm:2]** 
- The company's cash and bank balances declined to **S$2,854,958 (U.S.$2,244,640)** as of June 30, 2025, from S$4,970,367 at December 31, 2024, with **net cash used in operating activities totaling S$1,599,164 (U.S.$1,257,303)** for the six months ended June 30, 2025.  **[1873093_0001493152-25-016169_ex99-1.htm:2]** **[1873093_0001493152-25-016169_ex99-1.htm:3]** **[1873093_0001493152-25-016169_ex99-2.htm:3]** 
- CytoMed Therapeutics Ltd is advancing its lead product candidate, CTM-N2D, with the **Phase 1 clinical trial completing dose level 1 in June 2025** and dose level 2 currently underway.  **[1873093_0001493152-25-016169_ex99-2.htm:0]** 
- To bolster its financial position, the company entered into an **ATM Sales Agreement on August 18, 2025, allowing it to offer and sell ordinary shares up to an aggregate of U.S.$4.30 million**.  **[1873093_0001493152-25-016169_ex99-2.htm:4]** **[1873093_0001493152-25-016169_ex99-1.htm:14]**

CytoMed Therapeutics Ltd Reports Increased Net Loss and Initiates ATM Sales Agreement in Q2 2025

- CytoMed Therapeutics Limited (GDTC) announced a strategic reorganization to create a new cord blood-derived biotech, **LongevityBank Pte Ltd**, after successfully expanding clinical-scale natural killer (NK) cells from cord blood units.  **[1873093_0001641172-25-025761_form6-k.htm:0]** **[1873093_0001641172-25-025761_ex99-1.htm:0]** 
- This initiative builds on the **October 3, 2024**, asset acquisition of a licensed cord blood bank in Malaysia, IPSC Depository Sdn Bhd, which LongevityBank will leverage to focus on autologous therapies and re-start its cord blood banking business.  **[1873093_0001641172-25-025761_ex99-1.htm:0]** 
- Management and EP Capital Inc. intend to invest up to **US$500,000** in LongevityBank's equity to purchase new equipment and refurbish its laboratory, with plans to eventually spin off LongevityBank as a standalone biopharmaceutical company.  **[1873093_0001641172-25-025761_ex99-1.htm:0]**

CytoMed Therapeutics (GDTC)